HANNAH BRENDAN (Chief Business Officer) received a stock award from QUINCE THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 6/23/2025ACC: 0000912282-25-000697
Officer· Chief Business Officer
Since May 2022
+75.47K
Net shares
Net buyer
$45.3K
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
75.47K acquired
Non-Derivative Transactions1
Common Shares
Direct
Shares
+37.74K
Price / share
$1.20
Trade value
$45.28K
% of position
12.7%
6/18/2025
296.54K→334.28K
Total
Net shares
+37.74K
Net value
$45.28K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 6/18/2025 | A · Award | +37.74K | $1.20 | $45.28K | 12.7% | 296.54K | 334.28K |
| Total | +37.74K | $45.28K | ||||||
Derivative Transactions1
Warrants
Direct
Converts to
Common Shares
37.74K shares
Shares
+37.74K
Strike price
1.2
Held after
37.74K
Exercisable
—
6/18/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Warrants Direct | Common Shares37.74K shares | 6/18/2025 | A · Award | +37.74K | 1.2 | — | 37.74K |